Menu
Back to Journals » Clinical Ophthalmology » Volume 5
Age-related macular degeneration
Authors Querques G, Avellis, Querques, Bandello F , Souied E
Published 18 May 2011 Volume 2011:5 Pages 593—601
DOI https://doi.org/10.2147/OPTH.S10161
Review by Single anonymous peer review
Peer reviewer comments 2
Giuseppe Querques¹, Fernando Onofrio Avellis1,2, Lea Querques1,3, Francesco Bandello³, Eric H Souied¹
¹Service d'Ophtalmologie, Centre Hospitalier Intercommunal Créteil, Université Paris-Est Créteil, Créteil, France; ²Parma Eye Clinic University Hospital, Università degli Studi di Parma, Parma, Italy; ³Department of Ophthalmology, Università Vita-Salute San Raffaele Milano, Milano, Italy
Date of preparation: March 3, 2011
Conflict of interest: None declared
Clinical question: Is there any new knowledge about the pathogenesis and treatment of age-related macular degeneration (AMD)?
Results: We now understand better the biochemical and pathological pathways involved in the genesis of AMD. Treatment of exudative AMD is based on intravitreal injection of new antivascular endothelial growth factor drugs for which there does not yet exist a unique recognized strategy of administration. No therapies are actually available for atrophic AMD, despite some experimental new pharmacological approaches.
Implementation: strategy of administration, safety of intravitreal injection
Keywords: age-related macular degeneration, antivascular endothelial growth factor, choroidal neovascularization, drusen, geographic atrophy
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.